Fentora

Drug Teva Pharmaceuticals USA, Inc.
Total Payments
$12,754
Transactions
9
Doctors
8
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $12,754 9 8

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $12,754 9 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program Teva Pharmaceuticals USA, Inc. $12,754 8

Top Doctors Receiving Payments for Fentora

Doctor Specialty Location Total Records
, M.D Anesthesiology Naples, FL $4,264 2
, MD Internal Medicine Mansfield, NJ $1,424 1
, MD Anesthesiology River Ridge, LA $1,386 1
, M.D Pediatric Nephrology New York, NY $1,386 1
, MD Internal Medicine Penn Valley, PA $1,376 1
, MD Internal Medicine Baltimore, MD $1,039 1
, M.D., PH.D Clinical Pharmacology Kansas City, MO $1,013 1
, M.D Pulmonary Disease Park Ridge, NJ $867.57 1

About Fentora

Fentora is a drug associated with $12,754 in payments to 8 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..

Payment data is available from 2018 to 2018. In 2018, $12,754 was paid across 9 transactions to 8 doctors.

The most common payment nature for Fentora is "Unspecified" ($12,754, 100.0% of total).

Fentora is associated with 1 research study, including "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program" ($12,754).